View Older Stories View More Recent Stories

Oct 13, 2022 08:32AM GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
Oct 13, 2022 08:32AM GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
Oct 12, 2022 08:00AM VBI Vaccines (VBIV) and Agenus (AGEN) Collaborate to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab
Oct 12, 2022 08:00AM VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
Oct 12, 2022 08:00AM VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
Oct 12, 2022 08:00AM VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
Oct 5, 2022 08:30AM Agenus to Host “The Road Taken” R&D Event on November 12, 2022
Oct 5, 2022 08:30AM Agenus to Host “The Road Taken” R&D Event on November 12, 2022
Oct 5, 2022 08:00AM Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Oct 5, 2022 08:00AM Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Sep 12, 2022 08:30AM Agenus Initiates Botensilimab Phase 2 ACTIVATE Trials in Advanced MSS Colorectal Cancer and Advanced Melanoma
Sep 12, 2022 08:30AM Agenus Makes Senior Regulatory and Clinical Appointments
Sep 12, 2022 08:30AM Agenus Initiates Botensilimab Phase 2 ACTIVATE Trials in Advanced MSS Colorectal Cancer and Advanced Melanoma
Sep 12, 2022 08:30AM Agenus Makes Senior Regulatory and Clinical Appointments
Aug 9, 2022 08:00AM Agenus Provides Corporate Update and Second Quarter 2022 Financial Report
Aug 9, 2022 08:00AM Agenus Provides Corporate Update and Second Quarter 2022 Financial Report
Aug 2, 2022 08:30AM Agenus to Participate at BTIG Biotechnology Conference
Aug 2, 2022 08:30AM Agenus to Participate at BTIG Biotechnology Conference
Aug 1, 2022 08:30AM Agenus Announces First Patient Dosed in Phase 1 Study of AGEN1571 (anti-ILT2) in Advanced Solid Tumors
Aug 1, 2022 08:30AM Agenus Announces First Patient Dosed in Phase 1 Study of AGEN1571 (anti-ILT2) in Advanced Solid Tumors
Jul 27, 2022 08:30AM Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report
Jul 27, 2022 08:30AM Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report
Jun 30, 2022 08:30AM Agenus to Participate at William Blair’s Biotech Focus Conference
Jun 30, 2022 08:30AM Agenus to Participate at William Blair’s Biotech Focus Conference
Jun 29, 2022 07:02AM Agenus (AGEN) Reports Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer
Jun 29, 2022 07:00AM Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI Congress
Jun 29, 2022 07:00AM Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI Congress
Jun 21, 2022 08:30AM Agenus to Host Investor Webcast to Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI Congress
Jun 21, 2022 08:30AM Agenus to Host Investor Webcast to Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI Congress
Jun 10, 2022 08:02AM Agenus (AGEN) Announces GSK's RSV vaccine candidate for older adults, containing Agenus’ QS-21 STIMULON, reports positive pivotal data
Jun 10, 2022 08:00AM GSK’s RSV vaccine candidate for older adults, containing Agenus’ QS-21 STIMULON™ as part of GSK’s AS01 adjuvant, reports positive pivotal data supporting initiation of global regulatory submis
Jun 10, 2022 08:00AM GSK’s RSV vaccine candidate for older adults, containing Agenus’ QS-21 STIMULON™ as part of GSK’s AS01 adjuvant, reports positive pivotal data supporting initiation of global regulatory submis
May 31, 2022 08:30AM Agenus Advances Portfolio with 6 Clinical Collaborations
May 31, 2022 08:30AM Agenus Advances Portfolio with 6 Clinical Collaborations
May 25, 2022 08:30AM Agenus Announces Virtual Annual Shareholders Meeting
May 25, 2022 08:30AM Agenus to Participate at Jefferies Healthcare Conference
May 25, 2022 08:30AM Agenus Announces Virtual Annual Shareholders Meeting
May 25, 2022 08:30AM Agenus to Participate at Jefferies Healthcare Conference
May 24, 2022 08:30AM Agenus Announces Late-Breaking Oral Presentation at ESMO-GI and Strategies to Advance Botensilimab
May 24, 2022 08:30AM Agenus Announces Late-Breaking Oral Presentation at ESMO-GI and Strategies to Advance Botensilimab
May 10, 2022 08:00AM Agenus Corporate Update and First Quarter 2022 Financial Report
May 10, 2022 08:00AM Agenus Corporate Update and First Quarter 2022 Financial Report
Apr 26, 2022 08:30AM Agenus to Provide Corporate Update and First Quarter 2022 Financial Report
Apr 26, 2022 08:30AM Agenus to Provide Corporate Update and First Quarter 2022 Financial Report
Apr 8, 2022 01:00PM Agenus Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND Clearance
Apr 8, 2022 01:00PM Agenus Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND Clearance
Apr 5, 2022 08:33AM Agenus' (AGEN) CD137 Agonist Advances in the Clinic, Triggers Milestone Payment from Gilead
Apr 5, 2022 08:30AM Agenus’ CD137 Agonist (AGEN2373) Advances in the Clinic, Triggering Milestone Payment from Gilead
Apr 5, 2022 08:30AM Agenus’ CD137 Agonist (AGEN2373) Advances in the Clinic, Triggering Milestone Payment from Gilead
Mar 7, 2022 07:02AM Agenus (AGEN) and Targovax ASA Collaborate on Mutant KRAS Cancer Vaccine Adjuvanted with QS-21 STIMULON
View More Recent Stories View Older Stories